Table V.
Association between global DNA methylation level, classified by tertiles of the distribution of controls and breast cancer stratified by clinicopathologic features
| Groupa | T1 |
T2 |
T3 |
|||
| n | OR (95% CI) | n | OR (95% CI) | n | OR (95% CI) | |
| Controls | 58 | 58 | 57 | |||
| Histological grade | ||||||
| I/II | 15 | 1.0 (reference) | 18 | 1.20 (0.55–2.64) | 35 | 2.31 (1.13–4.75) |
| III | 18 | 1.0 (reference) | 30 | 1.67 (0.83–3.34) | 58 | 3.25 (1.69–6.24) |
| AJCC stage | ||||||
| I | 20 | 1.0 (reference) | 28 | 1.43 (0.72–2.85) | 64 | 3.27 (1.73–6.18) |
| II/III | 13 | 1.0 (reference) | 21 | 1.58 (0.72–3.49) | 30 | 2.29 (1.08–4.88) |
| Hormone status | ||||||
| ER+ and PR+ | 21 | 1.0 (reference) | 29 | 1.40 (0.71–2.75) | 59 | 2.84 (1.52–5.32) |
| ER− or PR− | 11 | 1.0 (reference) | 20 | 1.79 (0.78–4.08) | 32 | 2.86 (1.31–6.27) |
| Tumor size | ||||||
| <1 cm | 25 | 1.0 (reference) | 34 | 1.38 (0.73–2.62) | 76 | 3.11 (1.72–5.61) |
| 1 cm+ | 8 | 1.0 (reference) | 15 | 1.81 (0.71–4.65) | 18 | 2.19 (0.87–5.49) |
| Lymph node involvement | ||||||
| No | 24 | 1.0 (reference) | 36 | 1.52 (0.80–2.88) | 72 | 3.01 (1.65–4.50) |
| Yes | 9 | 1.0 (reference) | 13 | 1.42 (0.56–3.62) | 22 | 2.49 (1.04–5.95) |
AJCC, American Joint Committee on Cancer; T1, first tertile; T2, second tertile; T3, third tertile.
ORs by polychotomous logistic regression model adjusting for age (continuous variable), race (Caucasian, African-American) and batches.
a
T1 methylation level < 4.25; T2 4.25 ≤ methylation level < 4.50; T3 ≥ 4.50.